Top

Category: Mergers and Acquisitions


Mergers and Acquisitions

Novartis Acquires DTx Pharma in Deal Worth Up to $1 Billion

July 20, 2023

Via: Biopharm International

Novartis has acquired DTx Pharma, a US-based, preclinical-stage biotechnology company, for an upfront payment of $500 million plus additional payments of up to $500 million, dependent on the completion of pre-specified milestones, the companies announced in their respective July 17, […]


Mergers and Acquisitions

Vector Laboratories Acquires Quanta BioDesign

July 17, 2023

Via: Biopharm International

Vector Laboratories announced the acquisition of Quanta BioDesign on July 17, 2023, which further expands the former’s portfolio of bioconjugation linkers and dyes, as well as its manufacturing sector, according to the press release. “This acquisition is valuable because it […]


Mergers and Acquisitions

RNA editing specialist Korro to go public via reverse merger

July 14, 2023

Via: Biopharma Dive

Frequency has had a rocky year, recently undergoing a restructuring after an experimental drug for hearing loss failed to meet its goal in a clinical trial. The company shut down the program and laid off about half of its workforce […]


Mergers and Acquisitions

Applied DNA Acquires RNA Polymerase Developer Spindle Biotech

July 13, 2023

Via: Contract Pharma

Applied DNA Sciences, Inc. a company involved with PCR-based DNA technologies, acquired Spindle Biotech Inc., an early-stage, private biotech company developing next-generation RNA manufacturing technologies. The acquisition leverages the company’s LinearDNA platform that enables efficient chemical modification of DNA templates […]


Mergers and Acquisitions

Novartis to acquire kidney disease biotech Chinook for up to $3.5B

June 12, 2023

Via: Biopharma Dive

Novartis has agreed to acquire Chinook Therapeutics for as much as $3.5 billion, taking a chance that a pair of kidney disease drugs the biotechnology company has developed will succeed in late-stage testing. Under the deal announced Monday, Novartis will […]


Mergers and Acquisitions

Revvity, AstraZeneca Enter Next-Gen Gene Editing Platform Pact

May 18, 2023

Via: Contract Pharma

Revvity, a provider of health sciences services, entered a new license agreement with AstraZeneca for the technology underlying its Pin-point base editing system, a next-generation modular gene editing platform with a strong safety profile. The Pin-point system and the underlying […]


Mergers and Acquisitions

Gilead Acquires Privately Held Biotech XinThera

May 9, 2023

Via: Contract Pharma

Gilead Sciences, Inc. has acquired all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition adds clinical development pipeline assets for well-validated targets in oncology and inflammation. Through the acquisition, Gilead gains rights to a […]


Mergers and Acquisitions

Moderna, Novocol Pharma Partner on Fill-Finish Agreement for mRNA Vaccines

May 5, 2023

Via: Contract Pharma

Moderna, Inc., a provider of messenger RNA (mRNA) therapeutics and vaccines, entered into a long-term agreement with Ontario-based Novocol Pharma, a sterile injectable contract development and manufacturing organization (CDMO), to perform aseptic fill-finish, labelling and packaging of mRNA respiratory vaccines […]


Mergers and Acquisitions

Astellas to acquire eye drug developer Iveric Bio for $5.9B

May 1, 2023

Via: Biopharma Dive

Japanese drugmaker Astellas Pharma on Sunday agreed to acquire Iveric Bio for about $5.9 billion, betting that a medicine the biotechnology company has developed for a common type of vision loss can help it build an eye drug business. Astellas […]


Mergers and Acquisitions

Adaptive Biotechnologies Announces Collaboration with Takeda for Minimal Residual Disease Measures

April 28, 2023

Via: Biopharm International

Adaptive Biotechnologies Corporation announced on April 12, 2023 that it has begun a translational collaboration with Takeda. Adaptive Biotechnologies will use its clonoSEQ Assay to assess minimal residue disease (MRD) to start with the development and commercialization of Takeda’s pipeline […]


Mergers and Acquisitions

Merck to Purchase Prometheus Biosciences for $10.8 Billion

April 18, 2023

Via: Biopharm International

Merck and Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, announced an acquisition agreement on April 16, 2023. Merck will acquire all outstanding shares of the company for $200 per share, a total approximate equity valuation of approximately […]


Mergers and Acquisitions

BioNTech moves into ADCs with Duality deal

April 3, 2023

Via: Biopharma Dive

Armed with cash earned from sales of the COVID-19 vaccine it developed with Pfizer, BioNTech has been investing in cancer drug research and development — its primary focus prior to the pandemic. While BioNTech specializes in messenger RNA, it also […]


Mergers and Acquisitions

Pharma partner Sartorius eyes gene therapy market with $2.6B deal

March 31, 2023

Via: Biopharma Dive

Sartorius, a Germany-based manufacturer and supplier to the biopharmaceutical industry, is acquiring France’s Polyplus in a $2.6 billion acquisition meant to expand the company’s role as partner to gene and cell therapy developers. Under a deal announced Friday, Sartorius will […]


Mergers and Acquisitions

Junshi Biosciences, Rxilient Biotech Partner Develop Toripalimab in Southeast Asia

March 30, 2023

Via: Contract Pharma

Junshi Biosciences Co., Ltd and Rxilient Biotech entered into a collaboration for the development and commercialization of the anti-PD-1 monoclonal antibody drug, toripalimab, through joint venture in 9 Southeast Asian nations, including Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the […]


Cell and Gene Therapy, Industry, Mergers and Acquisitions

Regeneron bets on ‘Treg’ cell therapy with Sonoma deal

March 28, 2023

Via: Biopharma Dive

Regeneron became one of biotech’s most valuable companies through its success making antibody drugs. Its flagship technology, a way of testing potential medicines on genetically modified mice, has helped it unearth antibody treatments for eye diseases, autoimmune conditions, rare disorders […]


Mergers and Acquisitions

Curia and Corning Collaborate to Advance Biopharmaceutical Continuous-Flow Development

March 24, 2023

Via: Biopharm International

Curia announced on March 23, 2023 that it is collaborating with Corning to expand and accelerate continuous-flow development and manufacturing programs for the chemical and biopharmaceutical industries globally. The collaboration marks the first global installation of Corning’s G1 production system […]


Mergers and Acquisitions

Harm Reduction Therapeutics, Catalent Ink Naloxone Commercial Supply Pact

March 24, 2023

Via: Contract Pharma

Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths, signed a commercial supply agreement with Catalent for the manufacture Harm Reduction Therapeutics’ naloxone nasal spray, RiVive (3.0 mg), for the emergency treatment of […]


Clinical Trials, Mergers and Acquisitions, Research and Development

LEO Pharma, ICON Partner to Advance Clinical Trials in Dermatology

March 10, 2023

Via: Contract Pharma

LEO Pharma, a global leader in medical dermatology, and ICON plc, entered into a strategic partnership that will enable LEO Pharma to scale clinical trial execution that is patient-centric and cost effective, to support the company’s clinical portfolio. The partnership […]


Industry, Mergers and Acquisitions, Vaccines

Merck signs $922m deal with Opko Health unit for Epstein-Barr vaccine candidate

March 9, 2023

Via: PMLiVE

The partnership will see both companies advance MDX-2201 to an Investigational New Drug application filing, after which Merck will be responsible for clinical and regulatory activities, as well as product commercialisation. In exchange, Opko will receive an upfront payment of […]


Mergers and Acquisitions

Adaptimmune acquires struggling cell therapy rival following layoffs

March 6, 2023

Via: Biopharma Dive

The deal highlights the funding difficulties that development-stage biotechnology companies continue to face amid a sector-wide downturn that has weakened investor interest. This has led to a spate of layoffs and consolidation across the industry. Before the companies’ respective layoffs […]